Low dose vs intermediate-high dose cyclophosphamide vs G-CSF stem cell mobilization in multiple myeloma in the era of novel agents: a multicenter study

被引：0
|
作者：
Saraceni, Francesco [1 ]
Pezzi, Annalisa [1 ]
Chiarucci, Martina [2 ]
Olivieri, Attilio [2 ]
Zuffa, Eliana [1 ]
Martino, Massimo [3 ]
Laszlo, Daniele [4 ]
Lanza, Francesco [1 ]
机构：
[1] Ravenna Hosp, Ravenna, Italy
[2] Osped Riuniti Ancona, Ancona, Italy
[3] Osped Bianchi Melacrino Morelli, Reggio Di Calabria, Italy
[4] European Inst Oncol, Milan, Italy
来源：
BONE MARROW TRANSPLANTATION | 2018年 / 53卷
关键词：
D O I：
暂无
中图分类号：
Q6 [生物物理学];
学科分类号：
071011 ;
摘要：
P848
引用
收藏
页码：777 / 778
页数：2
相关论文
共 50 条
  • [31] Upfront plerixafor plus G-CSF versus cyclophosphamide plus G-CSF for stem cell mobilization in multiple myeloma: efficacy and cost analysis study
    S Afifi
    N G Adel
    S Devlin
    E Duck
    J Vanak
    H Landau
    D J Chung
    N Lendvai
    A Lesokhin
    N Korde
    L Reich
    O Landgren
    S Giralt
    H Hassoun
    Bone Marrow Transplantation, 2016, 51 : 546 - 552
  • [32] Stem Cell Mobilization with Ixazomib and G-CSF in Patients with Multiple Myeloma
    Buehler, Selina
    Akhoundova, Dilara
    Jeker, Barbara
    Legros, Myriam
    Seipel, Katja
    Daskalakis, Michael
    Bacher, Ulrike
    Pabst, Thomas
    CANCERS, 2023, 15 (02)
  • [33] EFFICIENT STEM CELL MOBILIZATION IN LENALIDOMIDE TREATED MULTIPLE MYELOMA PATIENTS CAN BE ACHIEVED BY MOBILIZATION WITH DCEP (DEXAMETHASONE, CYCLOPHOSPHAMIDE, ETOPOSIDE, CISPLATINUM) FOLLOWED BY HIGH-DOSE G-CSF
    Badin, S. M.
    Lendvai, N.
    Gounder, S. K.
    Rowley, S.
    Donato, M.
    Goldberg, S.
    Pecora, A.
    McBride, L. H.
    Schmidt, L.
    Donadio, K. A.
    McNeil, A.
    Siegel, D. S.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2008, 14 (02) : 68 - 68
  • [34] RESPONSE TO INDUCTION TREATMENT ADAPTED SELECTION OF MOBILIZATION REGIMEN IN MULTIPLE MYELOMA: THE G-CSF ALONE VERSUS HIGH-DOSE CYCLOPHOSPHAMIDE PLUS G-CSF REGIMEN
    Lee, J. Y.
    Kim, S. J.
    Jang, J. E.
    Suh, C.
    Lee, H.
    Yhim, H. Y.
    Lee, W. S.
    Min, C. K.
    Lee, J. H.
    Kim, J. S.
    HAEMATOLOGICA, 2014, 99 : 647 - 648
  • [35] Comparing Cyclophosphamide with G-CSF and Plerixafor with G-CSF As Stem Cell Mobilization (SCM) Regimens for Multiple Myeloma (MM) Patients: An Evaluation of Mobilization Efficacy and Toxicity
    Tan, Carlyn Rose C.
    Pancari, Philip A.
    Ulicny, John
    Martin, Mary Ellen
    Barta, Stefan Klaus
    Kropf, Patricia Lamont
    Fung, Henry C.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2016, 22 (03) : S136 - S136
  • [36] RESPONSE TO INDUCTION TREATMENT ADAPTED SELECTION OF MOBILIZATION REGIMEN IN MULTIPLE MYELOMA: THE G-CSF ALONE VERSUS HIGH-DOSE CYCLOPHOSPHAMIDE PLUS G-CSF REGIMEN
    Jungyeon, L.
    Jeong, K. Soo
    Eun, J. Ji
    Chelwon, S.
    Hyewon, L.
    Ho-Young, Y.
    Sik, L. Won
    Chang-Ki, M.
    Hoon, L. Jae
    Seok, K. Jin
    BONE MARROW TRANSPLANTATION, 2014, 49 : S525 - S526
  • [37] Outcomes of G-CSF alone vs G-CSF with upfront plerixafor vs G-CSF/chemotherapy for collection of autologous stem cells in patients with multiple myeloma.
    Talamo, Giampaolo
    George, Melissa
    Ehmann, W. Christopher
    Drabick, Joseph J.
    Mineishi, Shin
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [38] Intermediate versus standard dose of G-CSF for stem cell mobilization in healthy donors for allogeneic transplantation
    Kröger, N
    Renges, H
    Krüger, W
    Sonnenberg, S
    Gutensohn, K
    Dielschneider, T
    Cortes-Dericks, L
    Zander, A
    BONE MARROW TRANSPLANTATION, 2002, 29 : S17 - S17
  • [39] G-CSF plus preemptive plerixafor vs hyperfractionated CY plus G-CSF for autologous stem cell mobilization in multiple myeloma: effectiveness, safety and cost analysis
    A Antar
    Z K Otrock
    M A Kharfan-Dabaja
    H A Ghaddara
    N Kreidieh
    R Mahfouz
    A Bazarbachi
    Bone Marrow Transplantation, 2015, 50 : 813 - 817
  • [40] G-CSF plus preemptive plerixafor vs hyperfractionated CY plus G-CSF for autologous stem cell mobilization in multiple myeloma: effectiveness, safety and cost analysis
    Antar, A.
    Otrock, Z. K.
    Kharfan-Dabaja, M. A.
    Ghaddara, H. A.
    Kreidieh, N.
    Mahfouz, R.
    Bazarbachi, A.
    BONE MARROW TRANSPLANTATION, 2015, 50 (06) : 813 - 817
12345